Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorBAZINET, Richard P.
dc.contributor.authorMETHEREL, Adam H.
dc.contributor.authorCHEN, Chuck T.
dc.contributor.authorSHAIKH, Saame Raza
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorNADJAR, Agnes
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorJOFFRE, Corinne
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorLAYE, Sophie
ORCID: 0000-0002-3843-1012
IDREF: 11366883X
dc.date.accessioned2021-09-06T08:42:09Z
dc.date.available2021-09-06T08:42:09Z
dc.date.issued2019-07-03
dc.identifier.issn1090-2139en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/112091
dc.description.abstractEnThe results of several meta-analyses suggest that eicosapentaenoic acid (EPA) supplementation is therapeutic in managing the symptoms of major depression. It was previously assumed that because EPA is extremely low in the brain it did not cross the blood-brain barrier and any therapeutic effects it exerted would be via the periphery. However, more recent studies have established that EPA does enter the brain, but is rapidly metabolised following entry. While EPA does not accumulate within the brain, it is present in microglia and homeostatic mechanisms may regulate its esterification to phospholipids that serve important roles in cell signaling. Furthermore, a variety of signaling molecules from EPA have been described in the periphery and they have the potential to exert effects within the brain. If EPA is confirmed to be therapeutic in major depression as a result of adequately powered randomized clinical trials, future research on brain EPA metabolism could lead to the discovery of novel targets for treating or preventing major depression.
dc.language.isoENen_US
dc.title.enBrain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.bbi.2019.07.001en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed31278982en_US
bordeaux.journalBrain, Behavior, and Immunityen_US
bordeaux.page21-28en_US
bordeaux.volume85en_US
bordeaux.hal.laboratoriesNutriNeurO (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINRAEen_US
bordeaux.teamPsychoneuroimmunologie et Nutrition: Approches expérimentales et cliniquesen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Brain,%20Behavior,%20and%20Immunity&rft.date=2019-07-03&rft.volume=85&rft.spage=21-28&rft.epage=21-28&rft.eissn=1090-2139&rft.issn=1090-2139&rft.au=BAZINET,%20Richard%20P.&METHEREL,%20Adam%20H.&CHEN,%20Chuck%20T.&SHAIKH,%20Saame%20Raza&NADJAR,%20Agnes&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée